Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
Portfolio Pulse from
Anixa Biosciences presented positive data from its Phase 1 study of a breast cancer vaccine at the SITC Annual Meeting. The vaccine was safe, well-tolerated, and showed immune responses in over 70% of patients. A Phase 2 study is planned for 2025.
November 08, 2024 | 6:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Anixa Biosciences announced positive Phase 1 results for its breast cancer vaccine, showing safety and immune response in over 70% of patients. A Phase 2 study is planned for 2025.
The positive Phase 1 results and the planned Phase 2 study indicate progress in Anixa's breast cancer vaccine development, likely boosting investor confidence and potentially increasing the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100